HHS Grants Liability Protection to Pandemic Vaccine Manufacturers
Manufacturers of vaccines used to prevent potential avian pandemics will receive immunity from product liability claims, HHS announced on January 1.
Manufacturers of vaccines used to prevent potential avian pandemics will receive immunity from product liability claims, HHS announced on January 1.
The move, which triggers a provision of the Public Readiness and Emergency Preparedness Act passed in late 2005, would grant protection from such claims for parties involved in the preparation of reference strains and the development, manufacturing, testing, and administration of vaccines.
The notice said that the liability was granted “to encourage the design, development, clinical testing or investigation” of countermeasures, based on the “credible risk” that that an avian influenza outbreak could spread to humans.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
